Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

NCT04887870 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT04887870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04887870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
June 29, 2021
Completion date
September 25, 2025
Enrollment
49 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic solid malignancies